SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ZILA--test for oral cancer?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Fleming who wrote (31)6/17/1996 7:40:00 PM
From: Ivan Andrew   of 61
 
Dentist Survey of One results: Not much use, here. Turns out my friends' dentist is in the "New Age" crowd, and has a relatively young, healthy, non-smoking/drinking clientele. So he's not too dialed in to the oral cancer field. He has never heard of OraTest/Scan. Also, he didn't know of any of the BDTC distribution arms. As I said, not much use here. Oh, well...

Unrelated question: Regarding the number of ZILA shares outstanding, I hope someone can explain this to me. On the 1995 Balance sheet (p. 8 of the '95 annual report, under shareholders' equity, Common Stock) are the following two lines:

Common stock, $.001 par value-authorized 50,000,000 shares;
issued, 24,355,462 sh (1995) and 24,029,968 sh (1994)

Does this mean there are 48,385,430 shares (24,355,462 + 24,029,968) outstanding? Seems like a lot, and also means that ZILA's market cap is close to 400 Million. But I don't know how else to read it. Any help would be appreciated.

Thanks,

Ivan
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext